|Bid||74.12 x 400|
|Ask||74.14 x 700|
|Day's range||73.28 - 74.41|
|52-week range||63.76 - 88.85|
|PE ratio (TTM)||7.81|
|Earnings date||26 Jul 2017|
|Dividend & yield||2.08 (2.86%)|
|1y target est||76.70|
Is Gilead Sciences (GILD) poised for a beat next week? Guggenheim analyst Tony Butler sees Gilead earning $2.15 a share, a penny above the consensus forecast compiled by sell-side analyst, with operating revenue of $6.54 billion beating the $6.31 billion expected by the Street. Butler’s estimates for the full 2017 calendar year are also above consensus, with per-share earnings of $8.28 on operating revenue of $25.4 billion.
Bristol-Myers Squibb Company (BMY) is scheduled to report first-quarter 2017 results on Jul 27, before the opening bell. Last quarter, the company beat earnings estimates by 16.7%.
Buffett may not be the world's wealthiest person, but he arguably has the richest heart.